All In Biotech

NDA 021926 · Azurity

Treximet

Naproxen Sodium, Sumatriptan Succinate · Oral

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Apr 15, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

356

90 Phase 3, 11 recruiting

FAERS reports

1,422

464 serious, 24 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. ( 5.1 ) Sumatriptan and Naproxen Sodium Tablets is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history...

What it is approved for

From the label in effect Dec 24, 2024.

Sumatriptan and Naproxen Sodium Tablets is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Sumatriptan and Naproxen Sodium Tablets is a combination of sumatriptan, a serotonin (5-HT) 1b/1d receptor agonist (triptan), and naproxen sodium, a non-steroidal anti-inflammatory drug, indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. ( 1 ) Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. ( 1 ) Not indicated for the prophylactic therapy of migraine attacks. ( 1 ) Not indicated for the treatment of cluster headache. ( 1 ) Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Sumatriptan and Naproxen Sodium Tablets, reconsider the diagnosis of migraine before Sumatriptan and Naproxen Sodium Tablets is administered to treat any subsequent attacks. Sumatriptan and Naproxen Sodium Tablets is not indicated for the prevention of migraine attacks. Safety and effectiveness of Sumatriptan and Naproxen Sodium Tablets have not been established for cluster headache.

Mechanism: Sumatriptan and Naproxen Sodium Tablets contains sumatriptan and naproxen. Sumatriptan binds with high affinity to cloned 5-HT 1B / 1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of neuropeptide release. Sumatriptan and Naproxen Sodium Tablets has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Sumatriptan and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TREXIMET · NAPROXEN SODIUM 60MG; SUMATRIPTAN SUCCINATE EQ 10MG BASE · TABLET, ORAL · Discontinued
  • TREXIMET · NAPROXEN SODIUM 500MG; SUMATRIPTAN SUCCINATE EQ 85MG BASE · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.

All 356 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective189
  • nausea146
  • headache110
  • migraine93
  • dizziness89
  • vomiting77
  • pain74
  • anxiety72
  • fatigue68
  • feeling abnormal62
  • chest pain56
  • dyspnoea51

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2008141
2009246
2010140
201190
2012102
201374
201477
2015103
2016123
201787
201875
201950
202035
202124
202222
20239
202410
202512
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Treximet (Sumatriptan Succ/Naproxen Sod)

2024 spending

$749K

Beneficiaries

94

450 claims

Per beneficiary

$7,964

$131.17 per unit

View as table
YearSpending
2020$1,170,470
2021$1,816,361
2022$1,314,924
2023$1,160,491
2024$748,599

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,373 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.